v3.25.1
Discontinued operations and assets held for sale - Result from discontinued operations (Details) - EUR (€)
€ / shares in Units, shares in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disclosure of analysis of single amount of off-balance sheet arrangements [line items]      
Collaboration revenues € 240,786,000 € 239,724,000 € 241,249,000
Total net revenues 275,649,000 239,724,000 241,249,000
Cost of sales (34,863,000)    
Research and development expenses (335,459,000) (241,294,000) (269,797,000)
Sales and marketing expenses (17,193,000) (5,676,000) (3,480,000)
General and administrative expenses (117,245,000) (128,289,000) (135,155,000)
Other operating income 40,773,000 47,272,000 36,127,000
Other income 40,773,000 47,272,000 36,127,000
Operating loss (188,338,000) (88,263,000) (131,056,000)
Fair value adjustments and net currency exchange differences 95,795,000 16,252,000 51,498,000
Other financial income 91,128,000 80,249,000 18,563,000
Other financial expenses (1,670,000) (2,613,000) (9,854,000)
Income/loss before tax (3,085,000) 5,625,000 (70,849,000)
Net income from discontinued operations € 75,364,000 € 215,685,000 € (146,570,000)
Weighted average number of shares - Basic 65,897 65,884 65,699
Weighted average number of shares for the purpose of diluted earnings/loss (-) per share 65,897 65,884 65,699
Discontinued Operations [Member]      
Disclosure of analysis of single amount of off-balance sheet arrangements [line items]      
Product net sales € 11,475,000 € 112,339,000 € 87,599,000
Collaboration revenues 26,041,000 431,465,000 176,432,000
Total net revenues 37,516,000 543,804,000 264,031,000
Cost of sales (1,693,000) (18,022,000) (12,079,000)
Research and development expenses (8,152,000) (190,177,000) (245,286,000)
Sales and marketing expenses (11,520,000) (113,356,000) (144,075,000)
General and administrative expenses (1,087,000) (17,989,000) (9,776,000)
Other operating income 56,180,000 13,003,000 10,721,000
Operating loss 71,244,000 217,262,000 (136,464,000)
Fair value adjustments and net currency exchange differences   (13,000) (25,000)
Other financial income 4,230,000 679,000 15,000
Other financial expenses (12,000) (167,000) (7,825,000)
Income/loss before tax 75,462,000 217,761,000 (144,298,000)
Income taxes (98,000) (2,076,000) (2,272,000)
Net income from discontinued operations € 75,364,000 € 215,685,000 € (146,570,000)
Basic earnings/loss (-) per share from discontinued operations € 1.14 € 3.27 € (2.23)
Diluted earnings/loss (-) per share from discontinued operations. € 1.14 € 3.27 € (2.23)
Weighted average number of shares - Basic 65,897 65,884 65,699
Weighted average number of shares for the purpose of diluted earnings/loss (-) per share 65,942 65,933 65,699
Jyseleca business, classified as held for sale      
Disclosure of analysis of single amount of off-balance sheet arrangements [line items]      
Gain on disposal of subsidiaries € 52,500,000    
Jyseleca business, classified as held for sale | Europe      
Disclosure of analysis of single amount of off-balance sheet arrangements [line items]      
Product net sales 11,500,000 € 112,300,000 € 87,600,000
Jyseleca business, classified as held for sale | BE      
Disclosure of analysis of single amount of off-balance sheet arrangements [line items]      
Product net sales 700,000 8,100,000 7,300,000
Collaboration agreement for filgotinib      
Disclosure of analysis of single amount of off-balance sheet arrangements [line items]      
Collaboration revenues € 26,000,000 € 429,400,000 € 174,400,000